(Q57990732)

English

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

0 references

Rodney J. Hicks

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Jaroslaw Cwikla

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Gregory Kaltsas

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

ORCID Public Data File 2021

author name string

Eric Krenning

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Lisa Bodei

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Simona Grozinsky-Glasberg

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Rudolf Arnold

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Ivan Borbath

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Christos Toumpanakis

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Philippa Davies

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Dieter Hörsch

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Eva Tiensuu Janson

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Dik J Kwekkeboom

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Antibes Consensus Conference participants

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

publication date

13 April 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Neuroendocrinology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

105

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

295-309

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site.

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Cerebral deafferentiation in operated gliomas as a predictor for malignancy?

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

90Y-edotreotide for metastatic carcinoid refractory to octreotide

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate.

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion.

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Effects of therapy with [177Lu-DOTA 0,Tyr 3]octreotate on endocrine function

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate.

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Temozolomide-associated myelodysplasia 6 years after treatment of a patient with pancreatic neuroendocrine tumor.

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Myeloid neoplasms after chemotherapy and PRRT: myth and reality

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT)

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Gastroenteropancreatic neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Consensus on biomarkers for neuroendocrine tumour disease

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine Malignancies.

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT.

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

4-Step renal dosimetry dependent on cortex geometry applied to 90Y peptide receptor radiotherapy: evaluation using a fillable kidney phantom imaged by 90Y PET.

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland.

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

[177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study

1 reference

https://api.crossref.org/works/10.1159%2F000475526

21 January 2018

Identifiers

10.1159/000475526

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28402980%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57990732&oldid=1580948862"